Literature DB >> 27841821

Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy.

Ross A Davenport1, Maria Guerreiro, Daniel Frith, Claire Rourke, Sean Platton, Mitchell Cohen, Rupert Pearse, Chris Thiemermann, Karim Brohi.   

Abstract

BACKGROUND: Major trauma is a leading cause of morbidity and mortality worldwide with hemorrhage accounting for 40% of deaths. Acute traumatic coagulopathy exacerbates bleeding, but controversy remains over the degree to which inhibition of procoagulant pathways (anticoagulation), fibrinogen loss, and fibrinolysis drive the pathologic process. Through a combination of experimental study in a murine model of trauma hemorrhage and human observation, the authors' objective was to determine the predominant pathophysiology of acute traumatic coagulopathy.
METHODS: First, a prospective cohort study of 300 trauma patients admitted to a single level 1 trauma center with blood samples collected on arrival was performed. Second, a murine model of acute traumatic coagulopathy with suppressed protein C activation via genetic mutation of thrombomodulin was used. In both studies, analysis for coagulation screen, activated protein C levels, and rotational thromboelastometry (ROTEM) was performed.
RESULTS: In patients with acute traumatic coagulopathy, the authors have demonstrated elevated activated protein C levels with profound fibrinolytic activity and early depletion of fibrinogen. Procoagulant pathways were only minimally inhibited with preservation of capacity to generate thrombin. Compared to factors V and VIII, proteases that do not undergo activated protein C-mediated cleavage were reduced but maintained within normal levels. In transgenic mice with reduced capacity to activate protein C, both fibrinolysis and fibrinogen depletion were significantly attenuated. Other recognized drivers of coagulopathy were associated with less significant perturbations of coagulation.
CONCLUSIONS: Activated protein C-associated fibrinolysis and fibrinogenolysis, rather than inhibition of procoagulant pathways, predominate in acute traumatic coagulopathy. In combination, these findings suggest a central role for the protein C pathway in acute traumatic coagulopathy and provide new translational opportunities for management of major trauma hemorrhage.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27841821      PMCID: PMC5257267          DOI: 10.1097/ALN.0000000000001428

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  57 in total

1.  Early coagulopathy predicts mortality in trauma.

Authors:  Jana B A MacLeod; Mauricio Lynn; Mark G McKenney; Stephen M Cohn; Mary Murtha
Journal:  J Trauma       Date:  2003-07

2.  Mechanisms of early trauma-induced coagulopathy: The clot thickens or not?

Authors:  Geoffrey P Dobson; Hayley L Letson; Rajiv Sharma; Forest R Sheppard; Andrew P Cap
Journal:  J Trauma Acute Care Surg       Date:  2015-08       Impact factor: 3.313

3.  Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.

Authors:  Jonathan J Morrison; Joseph J Dubose; Todd E Rasmussen; Mark J Midwinter
Journal:  Arch Surg       Date:  2011-10-17

4.  Massive amounts of tissue factor induce fibrinogenolysis without tissue hypoperfusion in rats.

Authors:  Mineji Hayakawa; Satoshi Gando; Masahiro Ieko; Yoshinori Honma; Taeko Homma; Yuichiro Yanagida; Nobuhiko Kubota; Shinji Uegaki; Atsushi Sawamura; Hidesaku Asakura
Journal:  Shock       Date:  2013-06       Impact factor: 3.454

Review 5.  Animal models of trauma-induced coagulopathy.

Authors:  Daniel Frith; Mitchell J Cohen; Karim Brohi
Journal:  Thromb Res       Date:  2011-12-24       Impact factor: 3.944

Review 6.  Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations.

Authors:  David S Kauvar; Rolf Lefering; Charles E Wade
Journal:  J Trauma       Date:  2006-06

Review 7.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

8.  Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries.

Authors:  W H Bickell; M J Wall; P E Pepe; R R Martin; V F Ginger; M K Allen; K L Mattox
Journal:  N Engl J Med       Date:  1994-10-27       Impact factor: 91.245

9.  The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital.

Authors:  Harry K Stinger; Philip C Spinella; Jeremy G Perkins; Kurt W Grathwohl; Jose Salinas; Wenjun Z Martini; John R Hess; Michael A Dubick; Clayton D Simon; Alec C Beekley; Steven E Wolf; Charles E Wade; John B Holcomb
Journal:  J Trauma       Date:  2008-02

10.  The incidence and magnitude of fibrinolytic activation in trauma patients.

Authors:  I Raza; R Davenport; C Rourke; S Platton; J Manson; C Spoors; S Khan; H D De'Ath; S Allard; D P Hart; K J Pasi; B J Hunt; S Stanworth; P K MacCallum; K Brohi
Journal:  J Thromb Haemost       Date:  2013-02       Impact factor: 5.824

View more
  34 in total

1.  Preoperative thrombelastography maximum amplitude predicts massive transfusion in liver transplantation.

Authors:  Peter J Lawson; Hunter B Moore; Ernest E Moore; Gregory R Stettler; Thomas J Pshak; Igal Kam; Christopher C Silliman; Trevor L Nydam
Journal:  J Surg Res       Date:  2017-07-27       Impact factor: 2.192

Review 2.  Activated protein C in neuroprotection and malaria.

Authors:  Laurent O Mosnier
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

3.  Thromboelastometry and Thrombelastography Analysis under Normal Physiological Conditions - Systematic Review.

Authors:  Marcel Adler; Sandra Ivic; Nicolas S Bodmer; Hugo Ten Cate; Lucas M Bachmann; Walter A Wuillemin; Michael Nagler
Journal:  Transfus Med Hemother       Date:  2017-03-08       Impact factor: 3.747

Review 4.  Fibrinolysis in trauma: a review.

Authors:  M J Madurska; K A Sachse; J O Jansen; T E Rasmussen; J J Morrison
Journal:  Eur J Trauma Emerg Surg       Date:  2017-09-16       Impact factor: 3.693

5.  An engineered factor Va prevents bleeding induced by direct-acting oral anticoagulants by different mechanisms.

Authors:  Annette von Drygalski; Vikas Bhat; Andrew J Gale; Patricia M Averell; Thomas J Cramer; Darlene J Elias; John H Griffin; Laurent O Mosnier
Journal:  Blood Adv       Date:  2020-08-11

Review 6.  The Diagnosis and Treatment of Acute Traumatic Bleeding and Coagulopathy.

Authors:  Marc Maegele
Journal:  Dtsch Arztebl Int       Date:  2019-11-22       Impact factor: 5.594

Review 7.  The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology.

Authors:  Stefano Giordano; Luca Spiezia; Elena Campello; Paolo Simioni
Journal:  Intern Emerg Med       Date:  2017-05-05       Impact factor: 3.397

Review 8.  Trauma-induced coagulopathy: The past, present, and future.

Authors:  Lucy Z Kornblith; Hunter B Moore; Mitchell J Cohen
Journal:  J Thromb Haemost       Date:  2019-05-13       Impact factor: 5.824

9.  Systemic hyperfibrinolysis after trauma: a pilot study of targeted proteomic analysis of superposed mechanisms in patient plasma.

Authors:  Anirban Banerjee; Christopher C Silliman; Ernest E Moore; Monika Dzieciatkowska; Marguerite Kelher; Angela Sauaia; Kenneth Jones; Michael P Chapman; Eduardo Gonzalez; Hunter B Moore; Angelo D'Alessandro; Erik Peltz; Benjamin E Huebner; Peter Einerson; James Chandler; Arsen Ghasabayan; Kirk Hansen
Journal:  J Trauma Acute Care Surg       Date:  2018-06       Impact factor: 3.313

10.  Common haemostasis issues in major bleeding and critical illness.

Authors:  Divyansh Gulati; Alex Novak; Simon J Stanworth
Journal:  Clin Med (Lond)       Date:  2018-08       Impact factor: 2.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.